دورية أكاديمية
Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.
| العنوان: | Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. |
|---|---|
| المؤلفون: | Danve-Szatanek C; CHU Lyon, 69373 Lyon Cedex 08, Paris, France. christelle.szatanek@free.fr, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, Billaudel S, Chanzy B, Coste-Burel M, Finkielsztejn L, Fleury H, Hadou T, Henquell C, Lafeuille H, Lafon ME, Le Faou A, Legrand MC, Maille L, Mengelle C, Morand P, Morinet F, Nicand E, Omar S, Picard B, Pozzetto B, Puel J, Raoult D, Scieux C, Segondy M, Seigneurin JM, Teyssou R, Zandotti C |
| المصدر: | Journal of clinical microbiology [J Clin Microbiol] 2004 Jan; Vol. 42 (1), pp. 242-9. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 7505564 Publication Model: Print Cited Medium: Print ISSN: 0095-1137 (Print) Linking ISSN: 00951137 NLM ISO Abbreviation: J Clin Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology. |
| مواضيع طبية MeSH: | Acyclovir/*pharmacology , Antiviral Agents/*pharmacology , Simplexvirus/*drug effects, Adult ; Aged ; Aged, 80 and over ; Animals ; Bone Marrow Transplantation ; Chlorocebus aethiops ; Drug Resistance, Viral ; Female ; Humans ; Male ; Middle Aged ; Organ Transplantation ; Vero Cells |
| مستخلص: | Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which is widely used. We deemed it essential to conduct a wide and coordinated survey of the emergence of ACV-resistant HSV strains. We have formed a network of 15 virology laboratories which have isolated and identified, between May 1999 and April 2002, HSV type 1 (HSV-1) and HSV-2 strains among hospitalized subjects. The sensitivity of each isolate to ACV was evaluated by a colorimetric test (C. Danve, F. Morfin, D. Thouvenot, and M. Aymard, J. Virol. Methods 105:207-217, 2002). During this study, 3900 isolated strains among 3357 patients were collected; 55% of the patients were immunocompetent. Only six immunocompetent patients excreted ACV-resistant HSV strains (0.32%), including one female patient not treated with ACV who was infected primary by an ACV-resistant strain. Among the 54 immunocompromised patients from whom ACV-resistant HSV strains were isolated (3.5%), the bone marrow transplantation patients showed the highest prevalence of resistance (10.9%), whereas among patients infected by human immunodeficiency virus, the prevalence was 4.2%. In 38% of the cases, the patients who excreted the ACV-resistant strains were treated with foscarnet (PFA), and 61% of them developed resistance to PFA. The collection of a large number of isolates enabled an evaluation of the prevalence of resistance of HSV strains to antiviral drugs to be made. This prevalence has remained stable over the last 10 years, as much among immunocompetent patients as among immunocompromised patients. |
| References: | JAMA. 1999 Dec 15;282(23):2220-6. (PMID: 10605973) J Infect Dis. 1998 Aug;178(2):297-303. (PMID: 9697707) J Infect Dis. 2000 Jun;181(6):2055-8. (PMID: 10837192) Lancet. 1982 Feb 20;1(8269):421-3. (PMID: 6121091) J Infect Dis. 1982 Nov;146(5):673-82. (PMID: 6290575) Antiviral Res. 1983 Nov;3(4):223-34. (PMID: 6320716) J Gen Virol. 1986 Apr;67 ( Pt 4):753-8. (PMID: 3007662) J Biol Stand. 1986 Jul;14(3):201-11. (PMID: 3020058) Antimicrob Agents Chemother. 1987 Oct;31(10):1465-9. (PMID: 2829708) Proc Natl Acad Sci U S A. 1988 Sep;85(18):6672-6. (PMID: 2842788) N Engl J Med. 1989 Feb 2;320(5):293-6. (PMID: 2536136) N Engl J Med. 1989 Feb 2;320(5):297-300. (PMID: 2536137) J Gen Virol. 1989 Apr;70 ( Pt 4):869-79. (PMID: 2543763) J Virol. 1989 Nov;63(11):4913-8. (PMID: 2552170) Ann Intern Med. 1990 Mar 15;112(6):416-22. (PMID: 2155570) J Med Virol. 1992 Jan;36(1):1-12. (PMID: 1315366) N Engl J Med. 1993 Dec 9;329(24):1777-82. (PMID: 8232486) Bone Marrow Transplant. 1998 Sep;22(6):587-9. (PMID: 9758349) Proc Soc Exp Biol Med. 1964 Oct;117:145-50. (PMID: 14219928) Dermatology. 1995;190(2):177. (PMID: 7727847) J Antimicrob Chemother. 2000 Aug;46(2):324-5. (PMID: 10933664) Sex Transm Infect. 2000 Jun;76(3):183-7. (PMID: 10961195) Clin Infect Dis. 2000 Oct;31(4):927-35. (PMID: 11049772) Bone Marrow Transplant. 2000 Oct;26(8):903-5. (PMID: 11081393) Pediatr Infect Dis J. 2001 Nov;20(11):1083-6. (PMID: 11734717) Blood. 2002 Feb 1;99(3):1085-8. (PMID: 11807018) Antimicrob Agents Chemother. 2002 Sep;46(9):2848-53. (PMID: 12183237) Antimicrob Agents Chemother. 2002 Sep;46(9):3042-4. (PMID: 12183267) J Med Virol. 2002 Sep;68(1):99-104. (PMID: 12210436) J Virol Methods. 2002 Sep;105(2):207-17. (PMID: 12270654) N Engl J Med. 1982 Feb 11;306(6):343-6. (PMID: 6275267) J Infect Dis. 1994 Jan;169(1):193-6. (PMID: 8277181) Bone Marrow Transplant. 1996 May;17(5):813-7. (PMID: 8733703) Clin Infect Dis. 1995 Dec;21(6):1514-5. (PMID: 8749652) Antimicrob Agents Chemother. 1997 Dec;41(12):2686-92. (PMID: 9420039) J Infect Dis. 1998 Mar;177(3):543-50. (PMID: 9498430) Antimicrob Agents Chemother. 1998 Apr;42(4):868-72. (PMID: 9559798) Chemotherapy. 2000 May-Jun;46(3):195-7. (PMID: 10765035) |
| المشرفين على المادة: | 0 (Antiviral Agents) X4HES1O11F (Acyclovir) |
| تواريخ الأحداث: | Date Created: 20040113 Date Completed: 20040305 Latest Revision: 20210526 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC321677 |
| DOI: | 10.1128/JCM.42.1.242-249.2004 |
| PMID: | 14715760 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0095-1137 |
|---|---|
| DOI: | 10.1128/JCM.42.1.242-249.2004 |